Efficacy of Antifungal Therapy in a Nonneutropenic Murine Model of Zygomycosis

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Antimicrobial Agents and Chemotherapy

• Publication date

  2002-06-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1128/AAC.46.6.1953-1959.2002PMID 12019114PMCID PMC127262
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Oral terbinafine for treatment of pulmonaryPseudallescheria boydii infection refractory to itraconazole therapy

  2005cited by this paper
• Treatment of Absidia corymbifera infection in mice with amphotericin B and itraconazole.

  2001cited by this paper
• Acquired itraconazole resistance in Aspergillus fumigatus.

  2001cited by this paper
• Zygomycetes in human disease.

  2000influential reference
• Combination Antifungal Therapy in Treatment of Murine Pulmonary Mucormycosis: Roles of Quinolones and Azoles

  2000cited by this paper
• An evaluation of the in vitro activity of terbinafine.

  2000cited by this paper
• Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis.

  2000cited by this paper
• In-vivo itraconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis. EBGA Network. European research group on Biotypes and Genotypes of Aspergillus fumigatus.

  1999cited by this paper
• Current and Emerging Azole Antifungal Agents

  1999cited by this paper
• Versatile Fluorescent Staining of Fungi in Clinical Specimens by Using the Optical Brightener Blankophor

  1999cited by this paper
• In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi.

  1998influential reference
• Evaluation of Possible Correlations between Antifungal Susceptibilities of Filamentous Fungi In Vitro and Antifungal Treatment Outcomes in Animal Infection Models

  1998influential reference
• A murine model of zygomycosis by Cunninghamella bertholletiae

  1998cited by this paper
• Holding Owen

  1997cited by this paper
• Severe osteomyelitis due to the zygomycete Apophysomyces elegans

  1994cited by this paper
• In vitro susceptibility to 9 antifungal agents of 14 strains of Zygomycetes isolated from clinical specimens

  1994cited by this paper
• Treatment of murine pulmonary mucormycosis with SCH 42427, a broad-spectrum triazole antifungal drug.

  1994cited by this paper
• Interaction of terbinafine with human serum and serum proteins.

  1992cited by this paper
• Cure of zygomycosis caused by a lipase-producing Rhizopus rhizopodiformis strain in a renal transplant patient.

  1991cited by this paper
• Inactivity of terbinafine in a rat model of pulmonary aspergillosis

  1990cited by this paper
• Agents of mucormycosis and related species.

  1990cited by this paper
• Effects of deferoxamine, feroxamine and iron on experimental mucormycosis (zygomycosis).

  1989cited by this paper
• Treatment of experimental zygomycosis in guinea pigs with azoles and with amphotericin B.

  1989cited by this paper
• Experimental Zygomycosis Due to Rhizopus spp. Infection by Various Routes in Guinea‐Pigs, Rats and Mice

  1988cited by this paper
• Efficacies of four antifungal agents in experimental murine sporotrichosis

  1988cited by this paper
• Simple method of inducing sporulation by Apophysomyces elegans and Saksenaea vasiformis

  1988cited by this paper
• In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis.

  1987cited by this paper
• Bioassay for SF 86-327, a new antifungal agent

  1986cited by this paper
• In vivo bronchoalveolar macrophage defense against Rhizopus oryzae and Aspergillus fumigatus.

  1984cited by this paper
• National Committee for Clinical Laboratory Standards.

  1980cited by this paper
• Principles and practice of infectious diseases. Vols 1 and 2.

  1979cited by this paper
• Apophysomyces, a new genus of the Mucorales

  1979cited by this paper
• Observations on the localization of Absidia corymbifera in vivo.

  1978cited by this paper
• Factors determining the susceptibility of mice to experimental phycomycosis.

  1975cited by this paper
• I n-vivo it raconazole resistance of Aspergillus fumigatus in systemic murine aspergillosis

  year unknowncited by this paper

• Thamnostylum piriforme, a novel etiological agent of superficial mycosis.

  2024cites this paper
• Utility of itraconazole and terbinafine in mucormycosis: a proof-of-concept analysis

  2022cites this paper
• First reported case of Gilbertella persicaria in human stool: outcome of a community study from Segamat, Johor, Malaysia

  2020cites this paper
• Murine Models for Development of Anti-Infective Therapeutics

  2020cites this paper
• Mucormycosis due to Apophysomyces species complex- 25 years' experience at a tertiary care hospital in southern India.

  2020cites this paper
• Mucormycosis

  2019cites this paper
• Antifungal combinations in Mucorales: A microbiological perspective

  2019cites this paper
• Ketoacidosis alone does not predispose to mucormycosis by Lichtheimia in a murine pulmonary infection model

  2017cites this paper
• Antifungal resistance in mucorales.

  2017cites this paper
• Animal Models to Evaluate Anti-infective Pharmacodynamics

  2016cites this paper
• Agents of Mucormycosis and Entomophthoramycosis

  2014cites this paper
• Molecular characterization and in vitro antifungal susceptibility of 80 clinical isolates of mucormycetes in Delhi, India

  2014cites this paper
• Erratum to: Actinomucor elegans var. kuwaitiensis isolated from the wound of a diabetic patient

  2013influential citation
• Diagnosis and treatment of mucormycosis in patients with hematological malignancies: guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3)

  2013cites this paper
• Therapeutic Review: Terbinafine

  2012cites this paper
• Efficacy of posaconazole in a murine model of disseminated infection caused by Apophysomyces variabilis.

  2012cites this paper
• Cutaneous Mucormycosis in Tornado Survivors

  2011cites this paper
• Mucormycosis Caused by Unusual Mucormycetes, Non-Rhizopus, -Mucor, and -Lichtheimia Species

  2011cites this paper
• Lessons from animal studies for the treatment of invasive human infections due to uncommon fungi.

  2011cites this paper
• Agents of Systemic and Subcutaneous Mucormycosis and Entomophthoromycosis

  2011cites this paper
• Successful triple combination therapy of disseminated absidia corymbifera infection in an adolescent with osteosarcoma.

  2010cites this paper
• Molecular Detection and Identification of Zygomycetes Species from Paraffin-Embedded Tissues in a Murine Model of Disseminated Zygomycosis: a Collaborative European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Fungal Infection Study Group (EFISG) Evaluation

  2010cites this paper
• ESCMID Fungal Infection Study Group (EFISG) evaluation 3

  2010cites this paper
• Post-traumatic Lethal Form of Primary Cutaneous Zygomycosis in a Healthy Young Patient and Review of the Literature

  2009cites this paper
• In vitro activity of antifungals against Zygomycetes.

  2009cites this paper
• Aufbau eines PCR-verlaufskontrollierten Mausmodells zur Zygomykose

  2009cites this paper
• A comparison of the fungicidal activity of amphotericin B and posaconazole against Zygomycetes in vitro.

  2009cites this paper
• Activity of Posaconazole and Other Antifungal Agents against Mucorales Strains Identified by Sequencing of Internal Transcribed Spacers

  2009cites this paper
• Molecular Identification and In Vitro Antifungal Susceptibilities of 28 Zygomycetes Isolates: FIMUA-ECMM Survey of Zygomycosis in Italy

  2009cites this paper
• Use of terbinafine in rare and refractory mycoses.

  2008cites this paper
• Actinomucor elegans var. kuwaitiensis isolated from the wound of a diabetic patient

  2008cites this paper
• Management of fungal infections in cancer patients

  2008cites this paper
• In Vitro Susceptibilities of 217 Clinical Isolates of Zygomycetes to Conventional and New Antifungal Agents

  2007influential citation
• Absidia Corymbifera in an immune competent accident victim with multiple abdominal injuries: case report

  2007cites this paper
• Multidrug-resistant endosymbiotic bacteria account for the emergence of zygomycosis: A hypothesis.

  2007cites this paper
• Rhino-Orbitocerebral Mucormycosis Caused by Apophysomyces elegans

  2006cites this paper
• Invasive zygomycosis: update on pathogenesis, clinical manifestations, and management.

  2006cites this paper
• Zygomycosis: the re-emerging fungal infection

  2006cites this paper
• Nouveaux antifongiques et nouvelles stratégies thérapeutiques dans les aspergilloses et candidoses invasives

  2005cites this paper
• In vitro susceptibility of 15 strains of zygomycetes to nine antifungal agents as determined by the NCCLS M38‐A microdilution method

  2005cites this paper
• Zygomycosis

  2004cites this paper
• Unusual fungal infections in the intensive care unit

  2004cites this paper
• Improved Outcome of Zygomycosis in Patients with Hematological Diseases?

  2004cites this paper
• Extra Copies of the Aspergillus fumigatus Squalene Epoxidase Gene Confer Resistance to Terbinafine: Genetic Approach to Studying Gene Dose-Dependent Resistance to Antifungals in A. fumigatus

  2004cites this paper
• Invasive infections due to Apophysomyces elegans.

  2003cites this paper
• Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy.

  2003cites this paper
• Status of combination therapy for refractorymycoses Related review : Status of combination therapy for refractory mycoses

  2003cites this paper
• In vitro susceptibilities of zygomycetes to conventional and new antifungals.

  2003cites this paper
• Activity of Posaconazole in Treatment of Experimental Disseminated Zygomycosis

  2003cites this paper
• Efficacy of Liposomal Amphotericin B in Treatment of Systemic Murine Fusariosis

  2002cites this paper